October 3, 2024 02:50 PM EDT
People
R&D

Ex­clu­sive: Re­lay Ther­a­peu­tics cuts an­oth­er 10% of com­pa­ny, cit­ing con­tin­ued stream­lin­ing ef­forts

Max Bayer

Pharma Reporter

Re­lay Ther­a­peu­tics is lay­ing off 10% of its staff, or about 30 em­ploy­ees, in an ad­di­tion­al round of job cuts af­ter a small­er down­siz­ing in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi com­pa­nies may sell units im­pact­ed by Biose­cure — re­port

Flag­ship part­ners with key Sin­ga­pore R&D agency as it boosts APAC in­vest­ment

Eli Lil­ly re­solves short­age for tirzepatide, po­ten­tial­ly end­ing com­pounder­s' run

No­vo and Lil­ly out­line plans to mit­i­gate dis­rup­tions from US port strikes

Enara Bio’s $32.5M Se­ries B to sup­port lead dark anti­gen pro­gram for GI can­cers

sponsored

3 Tiers for AAV Po­ten­cy As­say De­vel­op­ment Suc­cess

A service from the Financial Times